

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

COALITION FOR AFFORDABLE DRUGS VI LLC

PETITIONER

V.

CELGENE CORPORATION

PATENT OWNER

---

CASE NO.: IPR2015-01103

PATENT NO. 6,315,720

FILED: OCTOBER 23, 2000

ISSUED: NOVEMBER 13, 2001

INVENTORS: BRUCE A. WILLIAMS, JOSEPH K. KAMINSKI

TITLE: METHODS FOR DELIVERING A DRUG TO A PATIENT WHILE  
AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN  
OR SUSPECTED OF BEING CAUSED BY THE DRUG

---

**PETITIONER'S CURRENT EXHIBIT LIST AS OF NOVEMBER 30, 2015  
PURSUANT TO 37 C.F.R. § 42.63(e)**

**PETITIONER'S CURRENT EXHIBIT LIST**  
(UPDATED NOVEMBER 30, 2015)

Exhibit No.	Exhibit Description	Date Filed
<b>1001</b>	U.S. Patent No. 6,315,720 to Bruce A. Williams and Joseph K. Kaminski, filed on Oct. 23, 2003, and issued on Nov. 13, 2001 (“the ‘720 Patent”)	04/23/15
<b>1002</b>	U.S. Patent No. 6,315,720 Prosecution History (“‘720 prosecution history”)	04/23/15
<b>1003</b>	U.S. Patent No. 6,045,501 to Marc Elsayed and Bruce Williams, filed on Aug. 28, 1998, and issued on Apr. 4, 2000 (“ <i>Elsayed</i> ”)	04/23/15
<b>1004</b>	U.S. Patent No. 6,063,026 to Mark A. Schauss and Patricia Kane, filed on Mar. 22, 1996, and issued on May 16, 2000 (“ <i>Schauss</i> ”)	04/23/15
<b>1005</b>	U.S. Patent No. 6,202,923 to Joseph H. Boyer <i>et al.</i> , filed on Aug. 23, 1999, and issued on Mar. 20, 2001 (“ <i>Boyer</i> ”)	04/23/15
<b>1006</b>	“Guideline for the clinical use and dispensing of thalidomide,” R.J. Powell and J.M.M Gardner-Medwin, <i>Postgrad Med. J.</i> (1994) 79, 901–904 (“ <i>Powell</i> ”)	04/23/15
<b>1007</b>	“Pharmacists’ role in clozapine therapy at a Veterans Affairs medical center,” Benjamin R. Dishman <i>et al.</i> , <i>Am. J. Hosp. Pharm.</i> (Apr. 1, 1994) 51, 899–901 (“ <i>Dishman</i> ”)	04/23/15
<b>1008</b>	U.S. Patent No. 5,832,449 to David W. Cunningham, filed on Nov. 13, 1995, and issued on Nov. 3, 1998 (“ <i>Cunningham</i> ”)	04/23/15
<b>1009</b>	U.S. Patent No. 6,055,507 to David W. Cunningham, filed on Aug. 20, 1998, and issued on Apr. 25, 2000 (“ <i>Cunningham Divisonal</i> ”)	04/23/15
<b>1010</b>	“A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin,” Allen A. Mitchell <i>et al.</i> , <i>New Eng. J. Med.</i> (Jul. 13, 1995) 333:2,	04/23/15

	101–06 (“ <i>Mitchell</i> ”)	
<b>1011</b>	“S.T.E.P.S. <sup>TM</sup> : A Comprehensive Program for Controlling and Monitoring Access to Thalidomide,” Jerome B. Zeldis <i>et al.</i> , <i>Clinical Therapeutics</i> (1999) 21:2, 319–30 (“ <i>Zeldis</i> ”)	04/23/15
<b>1012</b>	Transcript of the FDA’s “Forty-Seventh Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee,” Sept. 4, 1997 (“ <i>FDA Meeting Part 1</i> ”)	04/23/15
<b>1013</b>	Transcript of the FDA’s “Forty-Seventh Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee,” Sept. 5, 1997 (“ <i>FDA Meeting Part 2</i> ”)	04/23/15
<b>1014</b>	“CDC Meeting: 03/26/1997 Minutes and Agenda Regarding Thalidomide” (“ <i>CDC Meeting</i> ”)	04/23/15
<b>1015</b>	“Assessing the Effectiveness of a Computerized Pharmacy System,” Reed M. Gardner <i>et al.</i> , <i>Decision Support Systems in Critical Care</i> , 1994, M.M. Schabot <i>et al.</i> , eds. (“ <i>Gardner</i> ”)	04/23/15
<b>1016</b>	“Review of computer applications in institutional pharmacy—1975–1981,” Ken W. Burleson, <i>Am. J. Hosp. Pharm.</i> (1982) 39:53–70 (“ <i>Burleson</i> ”)	04/23/15
<b>1017</b>	“Interactive Voice Response Systems in Clinical Research and Treatment,” James C. Mundt, <i>Psychiatric Services</i> (May 1997) 48:5, 611–12, 623 (“ <i>Mundt</i> ”)	04/23/15
<b>1018</b>	“Passage of Chemicals into Human and Animal Semen: Mechanisms and Significance,” Thaddeus Mann and Cecelia Lutwak-Mann, <i>CRC Critical Reviews in Toxicology</i> (1982) 11:1, 1–14 (“ <i>Mann</i> ”)	04/23/15
<b>1019</b>	“Preparing for Thalidomide’s Comeback,” Cori Vanchieri, <i>Annals of Internal Med.</i> (Nov. 15 1997) 127:10, 951–54 (“ <i>Vanchieri</i> ”)	04/23/15
<b>1020</b>	“Development of a Computerized Drug Interaction Database (MedicomSM) for Use in a Patient Specific Environment, Arthur F. Shinn <i>et al.</i> , <i>Drug Inform. J.</i> (1983) 17:205–10 (“ <i>Shinn</i> ”)	04/23/15

<b>1021</b>	“Decision support for drug prescription integrated with computer- based patient records in primary care,” R. Linnarsson, <i>Med. Inform.</i> 18:2, 131–42 (“ <i>Linnarsson</i> ”)	04/23/15
<b>1022</b>	“A medication database – a tool for detecting drug interactions in hospital,” P.E. Grönroos <i>et al.</i> , <i>Eur. J. Clin. Pharmacol.</i> (1997) 53:13–17 (“ <i>Grönroos</i> ”)	04/23/15
<b>1023</b>	“Prevalence of Alcohol and Drug Abuse in Schizophrenic Inpatients,” M. Soyka <i>et al.</i> , <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> (1993) 242:362–72 (“ <i>Soyka</i> ”)	04/23/15
<b>1024</b>	“Alcohol, Cannabis, Nicotine, and Caffeine Use and Symptom Distress in Schizophrenia,” Edna Hamera <i>et al.</i> , <i>J. of Nervous and Mental Disease</i> (Sept. 1995) 183:9, 559–65 (“ <i>Hamera</i> ”)	04/23/15
<b>1025</b>	“Substance Abuse and Schizophrenia: Editors’ Introduction,” Thomas R. Kosten and Douglas M. Ziedonis, <i>Schizophrenia Bulletin</i> (1997) 23:2, 181–86 (“ <i>Kosten</i> ”)	04/23/15
<b>1026</b>	“Substance Abuse and Women on Welfare,” Jeffrey C. Menill, National Center on Addiction and Substance Abuse at Columbia University, June 1994 (“ <i>Menill</i> ”)	04/23/15
<b>1027</b>	Declaration of Jeffrey Fudin, R.Ph., B.S., Pharm.D., DAAPM, FCCP, FASHP (“ <i>Fudin Decl.</i> ”)	04/23/15
<b>1028</b>	Curriculum Vitae for Jeffrey Fudin, R.Ph., B.S., Pharm.D., DAAPM, FCCP, FASHP (“ <i>Fudin CV</i> ”)	04/23/15
<b>1029</b>	“Center for Drug Evaluation and Research Approval Package for Application Number: 18-662/S-038 (“ <i>Accutane Label</i> ”)	04/23/15
<b>1030</b>	“Joint Claim Construction and Prehearing Statement,” <i>Celgene Corp. v. Natco Pharma Ltd.</i> , NJD-2-10-cv-05197, Jul. 18, 2011 (“ <i>Celgene Claim Construction Brief</i> ”)	04/23/15
<b>1031</b>	“Center for Drug Evaluation and Research Approval Package for: Application Number NDA 20-785 Approval Letter(s),” Sept. 19, 1997, and Jul. 16, 1998 (“ <i>FDA Thalomid Approval Letters</i> ”)	04/23/15
<b>1032</b>	“Influence of Socially Desirable Responding in a Study of	04/23/15

	Stress and Substance Abuse,” John W. Welte and Marcia Russell, <i>Alcohol. Clin. Exp. Res.</i> (Jul./Aug. 1993) 17:4, 758–61 (“Welte”)	
<b>1033</b>	“Thalidomide Back—Under Strict Control,” <i>JAMA: Medical News and Perspectives</i> (Oct. 8, 1997) 278:14, 1135–37 (“JAMA”)	04/23/15
<b>1034</b>	Orange Book Drug Product Listing Corresponding to the ‘501 Patent, as published by the U.S. Food and Drug Administration on August 4, 2015	08/11/15
<b>1035</b>	Orange Book Drug Product Listing Corresponding to U.S. Patent No. 6,315,720, as published by the U.S. Food and Drug Administration on August 4, 2015	08/11/15
<b>1036</b>	Pricing Information for Revlamid® (lenalidomide) capsules from “Information for Vermont Prescribers of Prescription Drugs,” from Medi-Span and Celgene Corporation (July 1, 2015)	08/11/15
<b>1037</b>	Pricing Information for Thalomid® (thalidomide) capsules from “Information for Vermont Prescribers of Prescription Drugs,” from Medi-Span and Celgene Corporation (July 1, 2015)	08/11/15
<b>1038</b>	Pricing Information for Pomalyst® (pomalidomide) capsules from “Information for Vermont Prescribers of Prescription Drugs,” from Medi-Span and Celgene Corporation (July 1, 2015)	08/11/15
<b>1039</b>	<i>Celgene Corp. v. Barr Laboratories, Inc. et al.</i> , Complaint, filed January 18, 2007, U.S. Dist. Ct. New Jersey, Case No.: 2:33-av-00001	08/11/15
<b>1040</b>	<i>Celgene Corp. v. Natco Pharma Ltd.</i> , U.S. Dist. Ct. New Jersey, Complaint, Case No: 2:10-cv-05197-SDW-SCM	08/11/15
<b>1041</b>	<i>Celgene Corp. v. Lannett Holdings Inc., et al.</i> , Complaint, U.S. Dist. Ct. New Jersey, Case No. 2:15-cv-00697-SDW-SCM	08/11/15
<b>1042</b>	<i>Celgene v. Barr</i> , Stipulated Dismissal, dated and filed May 21, 2010, in U.S. Dist. Ct. New Jersey Case No. 2:07-cv-00286-SDW-MCA	08/11/15
<b>1043</b>	<i>International Union of Bricklayers and Allied Craft Workers Local 1 Health Fund v. Celgene Corp.</i> , Class Action Antitrust Complaint, filed November 7, 2014, U.S. Dist. Ct. New Jersey, 2:14-cv-06997-KSH-CLW	08/11/15

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.